MERCK'S
COMMITMENT
TO HEPATITIS C

An estimated 2.7-3.9 million Americans are living with chronic hepatitis C virus (HCV) infection, a disease that can lead to long-term health consequences like liver failure or liver cancer.

For more than 30 years, Merck has been at the forefront of the response to chronic HCV and our team continues to work tirelessly to advance scientific knowledge of this significant global public health issue.

IN THE PAST DECADE, MERCK'S CLINICAL DEVELOPMENT PROGRAMS IN CHRONIC HCV INFECTION HAVE:

ENROLLED APPROXIMATELY 10,000 PARTICIPANTS

INCLUDED MORE THAN 135 CLINICAL TRIALS IN
APPROXIMATELY 40 COUNTRIES

MERCK IS PROUD OF ITS CONTRIBUTIONS TOWARD ADVANCING THE SCIENCE OF CHRONIC HCV

Our pursuit of innovation will continue. As part of our longstanding leadership in infectious diseases, Merck is committed to broadening access to help make treatment an option for all patients infected with HCV. We will continue our collaborations with the scientific community, patient advocates, local governments and other stakeholders to accelerate our collective goal of addressing the burden of chronic HCV.

Learn more about Hepatitis C: A Silent Disease and Growing Concern